Atea Pharmaceuticals (AVIR) Cash from Investing Activities (2020 - 2026)

Atea Pharmaceuticals' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $29.7 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 65.26% year-over-year to $29.7 million in Q1 2026; TTM through Mar 2026 was $132.9 million, a 56.54% increase from a year earlier, with the FY2025 full-year figure at $188.8 million, up 236.5% from the prior year.
• Cash from Investing Activities eased to $29.7 million in Q1 2026 per AVIR's latest filing, from $46.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $124.7 million in Q2 2024 and bottomed at -$487.0 million in Q3 2022.
• The 5-year median for Cash from Investing Activities is $27.8 million (2023), against an average of -$8.3 million.
• Across the five-year window, Cash from Investing Activities jumped 55736.36% in 2023 and plunged 112.13% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $33.5 million in 2022, then fell by 17.07% to $27.8 million in 2023, then sank by 112.13% to -$3.4 million in 2024, then soared by 1482.55% to $46.6 million in 2025, then tumbled by 36.17% to $29.7 million in 2026.
• Per Business Quant, the three latest AVIR Cash from Investing Activities figures stand at $29.7 million (Q1 2026), $46.6 million (Q4 2025), and $41.3 million (Q3 2025).